- Home
- CIF vs CCEL Comparison
CIF vs CCEL Comparison
Compare CIF & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIF | CCEL |
|---|---|---|
| Founded | 1988 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Managed Health Care |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 32.7M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | CIF | CCEL |
|---|---|---|
| Price | $1.71 | $3.65 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 43.9K | 3.7K |
| Earning Date | 01-01-0001 | 10-15-2025 |
| Dividend Yield | 10.11% | ★ 10.75% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,747,500.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.47 | $3.57 |
| 52 Week High | $1.77 | $8.79 |
Technical Indicators
Market Signals| Indicator | CIF | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 41.78 |
| Support Level | $1.68 | $3.81 |
| Resistance Level | $1.76 | $4.38 |
| Average True Range (ATR) | 0.02 | 0.28 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 21.43 | 22.22 |
Price Performance
Historical ComparisonAbout CIF MFS Intermediate High Income Fund
Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.